The impact of scientific publications from Dana-Farber Cancer Institute is the highest of the 12 leading cancer centers in the United States, according to an analysis included in a report by The Lancet Oncology.
In listing the research productivity of a dozen leading U.S. cancer centers, the commission report showed Dana-Farber as having the highest "field-weighted citation impact" of its scientific publications during the 2011-2015 period.
Over that period, 3,202 Dana-Farber publications were cited 118,953 times in the scientific literature, the analysis showed, yielding a field-weighted citation impact of 4.62. The world average citation impact score is 1.00.
That means that, on average, Dana-Farber's citation impact is about 2 1/2 times greater than the average for the United States, which is 1.88. Of the 11 other U.S. cancer centers, the next highest score was 3.62.
"The fact that Dana-Farber's publications impact is over four times higher than the average oncology paper is impressive," said Barrett Rollins, MD, PhD, Dana-Farber's Chief Scientific Officer.
The analysis was originally published earlier this year in the Elsevier Cancer Research Report.
The Lancet Oncology journal released the Commission on Future Cancer Research Priorities in the U.S. on November 1.
The commission builds on and extends recommendations of the 2016 Cancer Moonshot Blue Ribbon Panel to create a road map and plan of action to accelerate research, treatment, symptom control, and health systems improvement. The project takes a deeper,
more detailed look at the Blue Ribbon Panel recommendations and sets priorities.
It features input from 54 clinician-scientists from around the U.S., including Dana-Farber's Brian Alexander, MD, MPH, Kenneth Anderson, MD, and Lindsay Frazier, MD.
These experts examined the status of various areas of cancer research and set goals for areas including precision prevention, early detection, immunotherapy, pediatric oncology, survivorship, and data-sharing.